Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Galecto (GLTO)
NASDAQ:GLTO
Galecto (GLTO) Stock Price & Analysis
186 Followers
GLTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.46 - $3.70
Previous Close$0.56
Volume319.10K
Average Volume (3M)153.24K
Market Cap
$15.07M
Enterprise Value-$12.10M
Total Cash (Recent Filing)$27.17M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Jul 31, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding27,112,697
10 Day Avg. Volume161,631
30 Day Avg. Volume153,240
Standard Deviation0.26
R-Squared0.05
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$9.00Price Target Upside1598.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Galecto News
Ownership Overview
21.02% Insiders
2.20% Mutual Funds
10.36% Other Institutional Investors
66.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GLTO FAQ
What was Galecto’s price range in the past 12 months?
Galecto lowest stock price was $0.46 and its highest was $3.70 in the past 12 months.
What is Galecto’s market cap?
Currently, no data Available
When is Galecto’s upcoming earnings report date?
Galecto’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were Galecto’s earnings last quarter?
Galecto released its earnings results on Apr 26, 2024. The company reported -$0.202 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.208.
Is Galecto overvalued?
According to Wall Street analysts Galecto’s price is currently Undervalued.
Does Galecto pay dividends?
Galecto does not currently pay dividends.
What is Galecto’s EPS estimate?
Galecto’s EPS estimate is -$0.24.
How many shares outstanding does Galecto have?
Galecto has 27,112,698 shares outstanding.
What happened to Galecto’s price movement after its last earnings report?
Galecto reported an EPS of -$0.202 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went up 4.478%.
Which hedge fund is a major shareholder of Galecto?
Currently, no hedge funds are holding shares in GLTO
---
Galecto Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (1598.75% Upside)
$9.00 (1598.75% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.92%
12-Months-Change
Fundamentals
Return on Equity
-78.56%
Trailing 12-Months
Asset Growth
-49.75%
Trailing 12-Months
Company Description
Galecto
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis & impact a broad range of fibrotic & related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
---
GLTO Stock 12 Month Forecast
Average Price Target
$9.00
▲(1598.75% Upside)
Technical Analysis
Fate Therapeutics
―
Cidara Therapeutics
―
Bioline RX Ltd Sponsored ADR
―
Kura Oncology
―
Best Analysts Covering GLTO
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-25.90%
reiterated a buy rating last month
Copying Jay Olson's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -25.90% per trade.
---